What is Exela Pharma Sciences?
Founded in 2005 and headquartered in Lenoir, North Carolina, Exela Pharma Sciences operates as an integrated specialty pharmaceutical entity. The company specializes in the development and manufacturing of proprietary and generic sterile injectable products. Its business model is bifurcated into two primary segments: Finished Drug Products and a Contract Development and Manufacturing Organization (CDMO). By maintaining significant cGMP-compliant sterile manufacturing capacity, Exela provides essential support to healthcare providers, ensuring a reliable supply chain for high-demand medical treatments. The firm's focus on quality control and operational excellence has positioned it as a critical partner for stakeholders navigating the complexities of modern drug production and distribution.
How much funding has Exela Pharma Sciences raised?
Exela Pharma Sciences has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in Exela Pharma Sciences
PPP
Public-Private Partnership
What's next for Exela Pharma Sciences?
With the infusion of this capital, Exela Pharma Sciences is well-positioned to accelerate its growth trajectory within the competitive CDMO market. The strategic allocation of these funds will likely focus on enhancing manufacturing throughput, optimizing supply chain resilience, and potentially expanding its portfolio of proprietary sterile injectables. As the pharmaceutical industry faces ongoing pressure to mitigate drug shortages, Exela's ability to scale its cGMP infrastructure will be a key driver of its long-term value proposition. Future developments will likely center on technological integration within its manufacturing facilities and the pursuit of new partnerships to broaden its reach in the global healthcare market.
See full Exela Pharma Sciences company page
